
You mean you don't appreciate when your biotech holding with fantastic data is up 40% in the premarket with 50% more upside to fair value, and then gets crushed to flat at open because risk at a large MM market sold a pod's holdings for blowing up on a MRNA short position, and then a quant momentum strategy shorts it because of the big pullback, and then a quant fund piles on the selling pressure by hedging their AI long trade by shorting interest rate risk out with a SMID cap biotech short, and then the stock is down 15% and no one knows why so an analyst publishes that obviously the stock is down because (pick random datapoint that doesn't matter) but in reality was just persuaded on a call with a pod PM to be bearish because they had a short position they needed to press and then that narrative gets entrenched and you're sitting here wondering why this company swung 60% down on great data and is financed through CF+ and trades at a big discount to some other biotech company and the world moves on to the next company with data tomorrow and no one cares to re-visit your company because it's a "catalyst desert" for 3 months? And pharma then passes over it and buys an undifferentiated pre-clinical private China asset instead of your company, which blows up on them a year later and they write it down but now your company needs to finance at a discount to the prior data? How could you not love that?
I miss the days when the price discovery was driven by good ol' fashion fundamental analysis. All quant algos and retail now fucking everything up.




























